New York, New York - Canopy, the leader in Enterprise AI for oncology, today announced findings on the potential of its EHR-integrated Remote Therapeutic Monitoring (RTM) Platform to reduce infection-related hospitalization in patients receiving treatment for hematologic malignancies, through earlier identification of infection-related symptoms and associated initiation of outpatient oral antibiotics.
Remote therapeutic monitoring reduces hospitalization due to infection in patients being treated for hematological malignancy will be featured in an oral presentation at the 2025 American Society of Hematology Annual Meeting:
Abstract Number: abs25-12229; Presentation ID 131
Date and Time: Saturday, December 6, 10:30 AM - 10:45 AM EST
Location: Room W230 at the Orange County Convention Center in Orlando, Florida
Patients being actively treated across a broad spectrum of hematological malignancies were invited to enroll in the study and report symptoms through the Canopy ePRO-based RTM system, which automatically triggered nurse review when severe or worsening symptoms were identified.
Findings show a reduction in infection-related hospitalizations among patients using the Canopy RTM system (2.6% vs. 4.5%; RR 0.48; p=0.0147). Additional analyses across infection-related outcomes—including emergency department utilization and outpatient antibiotic use—will be shared during the oral presentation.
Canopy will also be featured in a separate poster presentation that highlights how integrating patient-reported outcomes in real-world settings enables a more complete assessment of BTKi tolerability, offering complementary evidence to inform patient-centered treatment selection:
Abstract Number: abs25-13558; Presentation ID 2768
Date and Time: Saturday, December 6, 5:30 PM - 7:30 PM EST
Location: West Halls B3-B4
At the 2024 American Society of Hematology (ASH) meeting, Canopy presented data highlighting:
37% reduction in treatment discontinuation at three months¹ [ASH, 2024]
Improved early detection of toxicities with bispecific antibody therapies² [ASH, 2024]
Previous studies highlighting the potential impact of Canopy’s platform on oncology patient experience in real-world settings have demonstrated:
45% improvement in treatment persistence at three months³ [ASCO, 2022]
22% reduction in ER visits/hospitalizations per 100 patient months⁴ [ASCO, 2022]
88% patient engagement sustained at six months⁵ [JCO, 2022]
Potential to improve adherence and manage toxicities associated with oral anticancer medications⁶ [ASCO Quality, 2025]
Canopy is a leader in Enterprise AI for Oncology, providing practices with a unified platform for all the care that happens between visits and across patient services. Supporting a growing network of more than 2,000 oncology providers across more than 500 sites of care nationwide, Canopy enables practices to identify and prioritize patients who need help, resolve their issues using AI-native tools, and generate new reimbursement streams. For more information, visit www.canopycare.us.
Media Contact:
Kaitlin Hemric
kaitlin@canopycare.us
Interested in learning more? Contact our team using the button below.